Anavex Life Sciences Corp (AVXL)

[sokol]

TTT: Thank you. Ariana is coming right out with and stating ”efficacy”, ”actionable genetic variant biomakrers”, identification of patients that benefit from AVXL 2-73 and go on to say ”a confirmed response with ANAVEX 2-73”. These are strong and confident words.

”Ariana Pharma helps ANAVEX® demonstrate efficacy of its Alzheimer’s therapy in phase IIa clinical trial.

Ariana’s KEM® Artificial Intelligence technology has resulted in the identification of the first actionable genetic variant biomarkers, selecting a specified Alzheimer’s disease population, who demonstrated a confirmed response with ANAVEX®2-73.”